trending Market Intelligence /marketintelligence/en/news-insights/trending/b4uMQXMchWqnU13uYp1Nuw2 content esgSubNav
In This List

Sun Pharmaceutical recalls diabetes drug due to contamination

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Sun Pharmaceutical recalls diabetes drug due to contamination

Sun Pharmaceutical Industries Ltd. unit Sun Pharmaceutical Industries Inc. is voluntarily recalling two lots of type 2 diabetes drug Riomet due to microbial contamination.

The contamination was found during sample preparation for an antimicrobial preservative effectiveness testing being performed as part of the 12-month stability study interval.

Sun Pharmaceutical classified the recall as a retail level class 2 recall. According to the U.S. Food and Drug Administration, class 2 recalls occur when the use of or exposure to the violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

The product was manufactured for the company by a contract manufacturer.